BioMarin signs new deal for early-stage bone disease asset

BioMarin recently halted development of a rare disease drug that it had acquired in a $270 million transaction. Within a week, the company announced another deal to acquire an early‑stage asset aimed at a bone disease.

The size of the new transaction is reported to be comparable to the earlier $270 million acquisition, though exact terms were not disclosed.

No further details about the target asset, its development stage, or the partner were provided in the announcement.

The move underscores BioMarin's ongoing effort to expand its pipeline despite recent setbacks.